Miromatrix is proud to announce the recent publication of “Eliminating the Organ Transplant Waiting List - The Future with Perfusion Decellularized Organs” authored by Miromatrix’ Dominique Seetapun, Ph.D. and Jeff Ross, Ph.D. in the premier peer-reviewed journal SURGERY. This publication highlights the ability of Miromatrix’ patented technology to address the chronic need for transplantable organs.
Perfusion decellularization is a method that utilizes the native vasculature, ducts or cavities of any solid organ to decellularize an organ and leave behind an extracellular matrix (ECM) scaffold with the native architecture, vasculature and biochemical markers intact. It has advanced tissue engineering from thin constructs to the engineering of whole organs. In 2014, 20 patients died every day in the U.S. while waiting for an organ on the organ transplant waiting list. Patients who receive organ transplants are subject to the possibility of rejection and life-long immunosuppression. Perfusion decellularized organs have the potential to provide an ideal scaffold for recellularization and development of whole functional non-immunogenic transplantable organs. This review provides an overview of perfusion decellularization, progress in the field of whole bioengineered organs as well as potential future therapies that can be developed using perfusion decellularized scaffolds.
Click to view or download the peer-reviewed article published in the journal SURGERY.